Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Human

Cited:

Human

Applications

Validated:

Agonist Activity

Cited:

Immunohistochemistry-Paraffin, Neutralization, Flow Cytometry, Bioassay, Functional Assay

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 71903
View all TRAIL R2/TNFRSF10B Primary Antibodies »

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human TRAIL R2/TNFRSF10B
Met1-Glu182
Accession # CAG46696

Specificity

Detects human TRAIL R2/TNFRSF10B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R3, rhTRAIL R4, or rhDcR3.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Endotoxin Level

<0.10 EU per 1 μg of the antibody by the LAL method.

Scientific Data Images for Human TRAIL R2/TNFRSF10B Antibody

Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells.

Human TRAIL R2/TNFRSF10B Antibody Induces Apoptosis of Jurkat Cells.

Human TRAIL R2/TNFRSF10B Monoclonal Antibody induces apoptosis of the Jurkat human acute T cell leukemia cell line in a dose-dependent manner, as measured by Resazurin (Catalog # AR002). The ED50 for this effect is typically 2-12 ng/mL.
Detection of Human TRAILR2/TNFRSF10B by Western Blot

Detection of Human TRAILR2/TNFRSF10B by Western Blot

Cleavage of FRET probe is indicative of caspase activation.Cells were treated with (A) 0–300 ng/ml TRAIL for 2.5 hours or (B) 0–50 µg/ml anti-DR5 antibody for 20 h. The resultant cells were analyzed by western blotting using antibodies specific to caspase 3 (C3), caspase 8 (C8), and CFP/YFP. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human TRAILR2/TNFRSF10B by Functional

Detection of Human TRAILR2/TNFRSF10B by Functional

MB231_CFP-YFP cells retain sensitivity to TRAIL and anti-DR5 antibody.(A) Parental MB231 (filled black) and MB231_CFP-YFP (open clear) cells were treated with TRAIL (0–100 ng/ml) for 2.5 h or anti-DR5 antibody (0–200 µg/ml) for 20 h, at the indicated concentrations. Cell viability was determined by MTT assay. (B) Cells were treated as in A and analyzed for apoptosis by flow cytometry after staining with Annexin-V-APC and propidium iodide (PI). p-values were determined using a Student’s t-test. EC50 values were determined using nonlinear curve fitting as described in the Materials and Methods section. For each EC50 value, 95% confidence intervals reflecting the statistical accuracy are reported in Table 1. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of Human TRAILR2/TNFRSF10B by Functional

Detection of Human TRAILR2/TNFRSF10B by Functional

Cell-based FRET biosensor provides a quantifiable response to treatments of death receptor targeted cancer therapies.MB231_CFP-YFP cells were treated with (A) 0–300 ng/ml TRAIL for 2.5 h and (B) 0–100 µg/ml anti-DR5 antibody for 20 h. FRET was calculated and is represented using bar graphs on the left side of the panel. EC50 values were determined by nonlinear curve fitting to normalized FRET values plotted against the log values of TRAIL and anti-DR5 antibody concentration in molar (right side of the panel). (C) Confocal microscopy images showing changes in FRET in MB231_CFP-YFP cells treated with 0–25 ng/ml TRAIL for 2.5 h. A pronounced shift from YFP acceptor emission (yellow) to CFP donor emission (cyan) can be observed for cells treated with increasing concentration of TRAIL, with an excitation setting = 458 nm. Statistical analysis was performed as in Fig. 1 and 2. Image collected and cropped by CiteAb from the following publication (https://dx.plos.org/10.1371/journal.pone.0107010), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for Human TRAIL R2/TNFRSF10B Antibody

Application
Recommended Usage

Agonist Activity

2-12 ng/mL
Sample: Jurkat human acute T cell leukemia cell line

Formulation, Preparation, and Storage

Purification

Protein A or G purified from hybridoma culture supernatant

Reconstitution

Reconstitute at 0.5 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TRAIL R2/TNFRSF10B

Human TRAIL R2, also called DR5 and TRICK 2 is a type 1, TNF R family, membrane protein which is a receptor for TRAIL (APO2 ligand). In the new TNF superfamily nomenclature, TRAIL R2 is referred to as TNFRSF10B. TRAIL R2 cDNA encodes a 440 amino acid residue precursor protein containing extracellular cysteine-rich domains, a transmembrane domain and a cytoplasmic death domain. Among TNF receptor family proteins, TRAIL R2 is most closely related to TRAIL R1/DR4, sharing 55% amino acid sequence identity. Binding of trimeric TRAIL to TRAIL R2 induces apoptosis. The induction of apoptosis likely requires oligomerization of the receptor. The human TRAIL R2/Fc chimera neutralizes the ability of TRAIL to induce apoptosis. Besides TRAIL R2, an additional TRAIL R1/DR4, which tranduces apoptosis signaling, and two TRAIL decoy receptors, which antagonize TRAIL-induced apoptosis, have been reported.

References

  1. Chaudhary, P.M. et al. (1997) Immunity 7:821.
  2. Walczak, H. et al. (1997) EMBO J. 16:5386.
  3. Golstein, P. (1997) Curr. Biol. 7:R750.

Long Name

TRAIL Receptor 2

Alternate Names

CD262, DR5, TNFRSF10B, TRAILR2

Entrez Gene IDs

8795 (Human); 21933 (Mouse)

Gene Symbol

TNFRSF10B

UniProt

CAG46696

Additional TRAIL R2/TNFRSF10B Products

Product Documents for Human TRAIL R2/TNFRSF10B Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Human TRAIL R2/TNFRSF10B Antibody

For research use only

Citations for Human TRAIL R2/TNFRSF10B Antibody

Customer Reviews for Human TRAIL R2/TNFRSF10B Antibody

There are currently no reviews for this product. Be the first to review Human TRAIL R2/TNFRSF10B Antibody and earn rewards!

Have you used Human TRAIL R2/TNFRSF10B Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies